Contact Us
Drug Search Results
More Filters [+]

Asenapine

Alternative Names: asenapine, saphris, secuado, asenapinmaleat, sycrest
Latest Update: 2024-06-18
Latest Update Note: Clinical Trial Update

Product Description

Asenapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Asenapine is used alone or in combination with other medications to treat or prevent episodes of mania (frenzied, abnormally excited mood) or mixed mania (frenzied, abnormally excited mood and symptoms of depression) in adults and children 10 years of age and older with bipolar I disorder (manic depressive disorder; a disease that causes episodes of mania, episodes of depression and other abnormal moods). Asenapine is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a610015.html)

Mechanisms of Action: 5-HT2A Antagonist,D2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Sublingual

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States

Approved Indications: Schizophrenia | Bipolar Disorder | Schizophrenia

Known Adverse Events: Weight Gain | Bipolar Disorder | Dizziness | Schizophrenia

Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Asenapine

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20222759

P3

Not yet recruiting

Schizophrenia

None

Recent News Events

Date

Type

Title

09/26/2023

News Article

 Saphris (Asenapine) Market Upcoming Outlook 2023-2030

09/18/2023

News Article

 Asenapine Market Overall Study Report With Top Players and Their Future Strategies, 2023-2031

09/09/2023

News Article

 The Mood Stabilizers market is projected to experience growth over the forecast period of 2023 to 2030, driven by new trend analysis and competition tracking, with a CAGR of 6.4%.

08/02/2023

News Article

 Global Transdermal CNS Therapeutics Market Research 2023

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions